The future of targeted therapies

The partner-of-choice for targeted therapeutic delivery

Targeted Delivery

Device-based Delivery: Extroducer®

The Extroducer is a novel, modality-agnostic endovascular infusion catheter with the ability to delivery payload directly to targeted cardiac and pancreatic tissues and solid tumors.

Learn More

Regenerative Medicines

SmartCella has sharpened its focus on the Extroducer® technology platform further as its clearest path to revenue growth and long-term value creation across multiple disease areas.

As part of this shift, SmartCella is divesting its cell therapy programs SMART01 and SMART02, and the GMP facility in Tullinge. SmartCella also remains committed to finding partners for its proprietary platform for mRNA delivery, including the proof-of-concept program for Osteoarthritis, SMART03.

Learn More

We are

ScientistsInnovatorsEntrepreneursVisionaries

We are a drug delivery company pioneering innovative delivery solutions for targeted therapies

The main technology, the Extroducer®, is a modality-agnostic endovascular delivery device designed for localized delivery to hard-to-reach organs, tumors, and tissues. The Extroducer® is FDA 510(k)-cleared for use in peripheral (including abdominal) tissues to inject diagnostic and therapeutic solutions into the perivascular space.

About Us

Founded in 2014

Tullinge, Sweden

around 30 Employees

10 Nationalities

News & Updates from SmartCella

News & Updates

Extroducer® data for intramyocardial delivery presented at EuroPCR 2026 in Paris

SmartCella and Heqet Therapeutics enter into licensing agreement regarding the Extroducer® delivery platform

SmartCella och Heqet Therapeutics ingår licensavtal avseende leveransplattformen Extroducer®

Want to improve the targeting of your therapy?